Sirona Biochem Corp.
OOTC:SRBCFCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company News
Sirona Biochem Update to Shareholders on Financial Status and Operations
Sirona Biochem Announces Debenture Financing
Sirona Biochem Secures Strategic Investment Agreements and New Joint Venture with Promura GmbH
Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare's Landmark Report
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Product Rollout
GlycoProteMim Featured in Stonegate Healthcare's Latest Anti-Aging Research Report
SIRONA BIOCHEM Corporate Update April 2024
Sirona Biochem Announces Close of Private Placement
Sirona Biochem Announces 2023 Annual Meeting Results
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations
Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025
Sirona Biochem Provides Update on Loan
Sirona Biochem Engages Global Beauty Consulting
Sirona Biochem Announces Loan
Sirona Biochem Initiates Private Placement
CORRECTION -- Sirona Biochem Corporate Update January 2024
Sirona Biochem Corporate Update January 2024
Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™
Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molecule TFC-1326